The Animal PET-CT market—defined as the global revenue generated from sales and service of pre-clinical and companion-animal positron-emission tomography–computed-tomography systems—has become a critical barometer for translational research investment and advanced veterinary care. With the Animal PET-CT market size valued at USD 412 million in 2025, the sector is entering a high-growth window underpinned by a 9.4% CAGR (2026-2033) and a market forecast that sees revenues surpassing USD 835 million by 2033. This growth outlook is fueled by a convergence of macro drivers: chronic-disease modeling in genetically modified rodents, rising pet humanization demanding oncologic precision, and NIH budgets earmarking >USD 1.2 bn annually for molecular imaging. Technology shifts toward bench-top SiPM-based scanners, GMP-compliant on-site cyclotrons, and AI-enhanced 3-D reconstruction are compressing scan times by 40% while tightening competitive intensity among a concentrated cohort of OEMs (Siemens, PerkinElmer, Mediso, G.E., and Scintica). Regulatory momentum from the FDA’s Vet-LIRN and the EU’s Directive 2019/6 on veterinary radiopharmaceuticals is accelerating Good Clinical Practice standards, reshaping procurement cycles and elevating total cost-of-ownership benchmarks.
